Skip to main content

Table 3 Baseline characteristics of plantar warts according to treatment preference

From: The effect of patients’ preference on outcome in the EVerT cryotherapy versus salicylic acid for the treatment of plantar warts (verruca) trial

Characteristic Treatment preference P value
Salicylic acid Cryotherapy No preference
Type of verruca     
Mosaic 5/28 (17.9) 16/86 (18.6) 24/104 (23.1) 0.73
Non-mosaic 23/28 (82.1) 70/86 (81.4) 80/104 (76.9)  
Duration of verruca (months)     
N 26 80 100  
Mean(sd) 30.7 (27.5) 22.9 (19.6) 26.6 (27.3) 0.43
Median (interquartile range) 24.0 (12.0, 39.0) 18.0 (9.5, 29.0) 16.8 (8.5, 36.0)  
Number of verrucae at baseline     
N 28 86 101  
Mean (sd) 4.3 (4.5) 3.8 (6.6) 3.3 (3.3) 0.50
Median (interquartile range) 3.0 (1.0, 5.5) 2.0 (1.0, 4.0) 2.0 (1.0, 4.0)  
Previous treatment for current verruca     
Yes 23/28 (82.1) 66/84 (78.6) 79/104 (76.0) 0.78
No 5/28 (17.9) 18/84 (21.4) 25/104 (24.0)  
Type of previous treatment*     
Self-treatment 21/23 (91.3) 53/66 (80.3) 73/80 (91.3) 0.15
Podiatrist/chiropodist 5/23 (21.7) 23/66 (34.9) 20/79 (25.3) 0.34
GP 10/23 (43.5) 30/66 (45.5) 27/80 (33.8) 0.32
Trial investigating verruca treatments 0/23 (0.0) 2/66 (3.0) 0/79 (0.0) 0.41
Other 3/23 (13.0) 6/66 (9.1) 5/79 (6.3) 0.50
  1. Values are n/N (%) unless otherwise stated.
  2. * Patients may have more than one previous verruca treatment.